¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Toxic agent syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼ºÈ£Èí±âº´À¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù.
¿µ¹® syndrome ÇÑ±Û ÁõÈıº
¼³¸í   
  Áõ»óÀÇ ÁýÇÕ. ¾î¶² Áúº´ÀǠ¡ÈÄÀÇ ÃÑÇÕÀ» ¸»ÇÑ´Ù. ´ë°³ ±× ¿øÀÎÀº ¾Ë ¼ö ¾øÀ¸³ª, Áõ»óÀÌ º¹ÇÕÀûÀ¸·Î ³ªÅ¸³ª°í ÀÌ¿¡ ´ëÇÑ Ä¡·á°¡ ÀÏÁ¤ÇÑ °æ¿ì ÇϳªÀÇ ÁõÈıºÀ¸·Î Ãë±ÞÇÑ´Ù.
¿µ¹® asphycitic syndrome ÇÑ±Û Áú½ÄÁõÈıº
¼³¸í   
  È£Èí±âÁßÀÇ »ê¼Ò°áÇÌ¿¡ ÀÇÇÑ »ý¸íÁ¤ÁöÀÇ Àý¹ÚÇÑ »óÅÂ, ¶Ç´Â ½ÇÁ¦·Î Á¤Áö°¡ ÀϾ »óÅÂ, °íÀÌ»êȭź¼ÒÁõ°ú Àú»ê¼ÒÁõ È¤Àº ¹«»ê¼ÒÁõ µîÀÌ µ¿¹ÝµÈ´Ù. ¿Ü°è ÆóÀÇ °íÅëÀÌ µÎÀýµÇ¾î ÆóÀǠȣÈíÀÛ¿ëÀÌ Àå¾ÖµÇ´Â °Í(¿ÜÁú½Ä)°ú °¡½º³ª ¾àÁ¦¿¡ ÀÇÇØ »ýü³» Á¶Á÷ÀÇ °¡½º±³È¯ÀÌ ¹æÇظ¦ ¹Þ´Â °Í(³»Áú½Ä)ÀÌ ÀÖ´Ù. ÀϹÝÀûÀ¸·Î ¿ÜÁú½ÄÀ» °¡¸®Å°´Â °æ¿ì°¡ ¸¹´Ù. ¿øÀÎÀ¸·Î¼­´Â ÄÚ³ª ÀÔ µî È£ÈíÀÔ±¸ÀÇ Æó»ö, À½½Ä¹°À̳ª À̹°¿¡ ÀÇÇÑ ±âµµÆó»ö, ¸ñÁ¶ÀÓ, ¹° ¶Ç´Â ºÐºñ¹° µîÀÌ ±âµµ·Î µé¾î°¡´Â °Í, ¾à¹° ¶Ç´Â ÆÄ»ódz¿¡ ÀÇÇѠȣÈí±Ù¸¶ºñ, ¸Å¸ô µî ¿Ü·Â¿¡ ÀÇÇѠȣÈí¿îµ¿ÀÇ ÀúÁö, °ø±â ÁßÀÇ »ê¼ÒºÎÁ· ¹× À¯µ¶°¡½ºÀÇ ÈíÀÔ µîÀ» µé ¼ö ÀÖ´Ù.
¿µ¹® nephrotic syndrome ÇÑ±Û ÄáÆÏÁõÈıº
¼³¸í   
  ÄáÆÏÀÇ Å丮À̻󿡠ÀÇÇÑ ´Ü¹éÁú¼Õ½ÇÀÌ ÁÖ¿øÀÎÀΠº´ÀÌ´Ù. ±× Á¤ÀǴ ¼ºÀÎÀÇ ¿ä´Ü¹é·®(¼Òº¯¿¡ ¼¯¿© ³ª¿À´Â ´Ü¹éÁúÀÇ ¾ç. ´ë°³ Á¤»óÀο¡¼­´Â ³ª¿ÀÁö ¾Ê°Å³ª, È¤Àº ¾ÆÁÖ ¼Ò·®ÀÌ ³ª¿Ã »ÓÀÓ)ÀÌ ÇÏ·ç 3.5mgÀÌ»ó, ¶ÇÇÑ ¼Ò¾Æ¿¡¼­´Â Ç÷Áß ¾ËºÎ¹Î³óµµ°¡ 2.5mgÀÌÇÏ, ÇÏ·íµ¿¾È ¼Òº¯À¸·Î ³ª¿À´Â ¿ä´Ü¹é·®À» ½Ã°£´ç °è»êÇßÀ» ¶§ ½Ã°£´ç 40mgÀÌ»óÀΠ°æ¿ìÀÌ´Ù. µû¶ó¼­ ÄáÆÏÁõÈıºÀ̶õ À§ÀÇ Á¤ÀÇ¿¡ ÇÕ´çÇϱ⸸ Çϸ頸ðµÎ ÇØ´çµÇ¹Ç·Î, ¿©·¯ °¡Áö ¿øÀο¡ ÀÇÇÑ ÄáÆÏÀÌ»óÀ¸·Î¼­ ´Ü¹éÁúÀÇ Áö³ªÄ£ ¹èÃâÀ» ³ªÅ¸³»´Â Áúº´ÀÇ ÁýÇÕü¸¦ ¶æÇÑ´Ù. ´ë°³ Áõ»óÀº Áö³ªÄ£ Ç÷ÁߴܹéÁúÀÇ °¨¼Ò·Î ÀÎÇÑ ºÎÁ¾, ±×¸®°í ÀÌÂ÷ÀûÀΠÁõ»óÀ¸·Î ¹ß»ýÇÑ °íÁöÁúÇ÷Áõ, °¨¿°°¨¼ö¼ºÀÇ Áõ°¡, °íÇ÷¾Ð µîÀÌ´Ù. Ä¡·á¿Í ¿¹ÈĴ ÄáÆÏÁõÈıºÀ» ³ªÅ¸³»´Â °¢ ¿øÀο¡ µû¶ó ´Ù¸£³ª, ´ë°³ ¼Ò¾Æ¿¡ ¹ß»ýÇÑ °æ¿ì ½ºÅ×·ÎÀ̵åÁ¦Àç¿¡ ÀÇÇÑ Ä¡·áÈ¿°ú°¡ ³ô´Ù.
¿µ¹® Cushing's syndrome ÇÑ±Û Äí½ÌÁõÈıº
¼³¸í   
  Äí½ÌÁõÈıºÀ̶õ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ¸¸¼ºÀûÀ¸·Î °úÀ׺кñ¿¡ ÀÇÇØ¼­ ÀϾ´Â º´À» ¸»ÇÑ´Ù.
  
  ¿øÀÎÀ¸·Î ¨ç ³úÇϼöü¿¡¼­ ACTH°¡ °úÀ× ºÐºñµÇ´Â °æ¿ì: ³úÇϼöü¿¡¼­ ACTH°¡ ³Ê¹«³ª ¸¹ÀÌ ºÐºñµÇ´Â °æ¿ì¿¡ ºÎ½Å°ÑÁúÀ» ÀÚ±ØÇؼ­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÈ´Ù. ¨è ³úÇϼöü ÀÌ¿ÜÀÇ ºÎºÐ¿¡¼­ ACTH°¡ ¸¹ÀÌ ºÐºñµÇ´Â °æ¿ì: Æó¾Ï, ³­¼Ò¾Ï µîÀÇ Á¾¾ç¿¡¼­ ACTH¸¦ »ý»êÇϴ °æ¿ì°¡ ÀÖ´Ù. ÀÌ °æ¿ì¿¡µµ ¿ª½Ã ºÎ½ÅÇÇÁúÀÌ ÀÚ±ØÀÌ µÇ¾î¼­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÈ´Ù. ¨é ACTHÀÇ ÀÚ±ØÀÌ ¾øÀÌ ºÎ½Å¿¡¼­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ³ª¿À´Â °æ¿ì. ACTHÀڱؿ¡ °ü°è¾øÀÌ ºÎ½ÅÇÇÁúÀÇ °úÀ×¼ºÀå, Á¾¾ç¿¡ ÀÇÇØ¼­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ºÐºñµÇ´Â °æ¿ì. ¨ê ¿ÜÀμº, ÀÇÀμº: Ä¡·á¸¦ À§Çؼ­ ¸¹Àº ¾çÀÇ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵带 Àå±â Åõ¿©ÇÒ °æ¿ì¿¡ »ý±â´Â Äí½ÌÁõÈıº
  
  Äí½ÌÁõÈıº¿¡¼­ Æ¯È÷ ¨ç¹ø¿¡ ÇØ´çÇϴ °ÍÀ» Äí½Ìº´¶ó°í ÇÑ´Ù.
  
  Áõ»óÀº ¶×¶×ÇÏ°í ¾ó±¼ÀÌ ´Þµ¢ÀÌó·³ µÕ±Û°í »ìÀÌ ÂÈÁö¸¸ ÆÈ, ´Ù¸®´Â °¡´Ã°í ´ë½Å¿¡ ¸ö¿¡ ¸¹Àº »ìÀÌ ºÙ¾îÀÖ´Ù. ¸ñµÚ¿¡ ¸¹Àº »ìÀÌ À־ ±×°ÍÀÌ µ¢¾î¸®¸¦ Çü¼ºÇϱ⵵ ÇÑ´Ù. À̰ÍÀº ¿ø·¡ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 Áö¹æÀ» ºÐÇØÇϴ ¿ªÇÒÀ» ÇÏÁö¸¸ º´ÀûÀ¸·Î ¸¹ÀÌ ³ª¿Ã °æ¿ì¿¡´Â Áö¹æÀÇ ºÐÆ÷¸¦ º¯È­½Ã۴ ¿ªÇÒÀ» Çϱ⠶§¹®ÀÌ´Ù. Áï ÆÈ, ´Ù¸® µîÀÇ ¿Â¸ö¿¡ ÆÛÁ®Àִ Áö¹æÀ» ¸öÅëÂÊÀ¸·Î ¸ðµÎ À̵¿½ÃŲ´Ù. ÀÜÅÐÀÌ ¿Â¸ö¿¡ °ÉÃļ­ ¸¹ÀÌ ³ªÀÖ°í ¿©µå¸§ÀÌ ¸¹°í ¹è¿¡ ÀÚÁÖ»ö ¼±Á¶°¡ Àִ °æ¿ì°¡ ¸¹´Ù. ±×¸®°í ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵尡 ´Ü¹éÁúÀ» ºÐÇØÇØ¼­ ´ç·ù¸¦ ¸¸µå´Â ¿ªÇÒÀ» ÇÏ¿© ±ÙÀ°À̳ª »À´ëÀÇ ½ÉÇÑ ¼Ò½ÇÀÌ ÀÖ´Ù. ±×·¡¼­ ±ÙÀ°ÀÌ °ÅÀÇ ¾ø¾îÁö°í »À´Â ¾ÆÁÖ ºÎ·¯Áö±â ½±°Ô µÈ´Ù. ´ë°³ °íÇ÷¾ÐÀΠ°æ¿ì°¡ ¸¹°í ½É¸®ÀûÀ¸·Î ¿ì¿ïÁõÀ̳ª °ú¹Î¼º µîÀÌ ÀÖÀ» ¼öµµ ÀÖ°í ½ÉÇÑ °æ¿ì¿¡´Â Á¤½Åº´Áõ¼¼¸¦ º¸À̱⵵ ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • hyperosmotic agent
    °í»ïÅõ¾ÐÁ¦
  • health care agent
    1. °Ç°­°ü¸®¿ä¿ø 2. °Ç°­°ü¸®±â±¸
  • ischemia-inducing agent
    ÇãÇ÷À¯µµÁ¦
  • induction agent
    À¯µµ¹°Áú, À¯µµÁ¦
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
  • lipotropic agent
    Ä£Áö¹æÁ¦
  • mucolytic agent
    Á¡¾×¿ëÇØÁ¦
  • mutagenic agent
    µ¹¿¬º¯ÀÌ¿ø
  • masking agent
    Â÷ÆóÁ¦
  • oral hypoglycemic agent
    °æ±¸Ç÷´ç°­ÇÏÁ¦
  • oxidizing agent
    »êÈ­Á¦
  • pressor agent
    ½Â¾ÐÁ¦, Ç÷¾Ð»ó½ÂÁ¦
  • protective agent
    º¸È£Á¦
  • proteolytic agent
    ´Ü¹éÁúºÐÇØÁ¦
  • reducing agent
    ȯ¿øÁ¦, ȯ¿ø½Ã¾à
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • irritable bowel syndrome
    °ú¹Î´ëÀåÁõÈıº
  • Kallmann syndrome
    Ä®¸¸ÁõÈıº
  • Klinefelter's syndrome
    Ŭ¶óÀÎÆçÅÍÁõÈıº
  • Korsakoff's syndrome
    ÄÚ¸£»çÄÚÇÁÁõÈıº
  • locked-in syndrome
    °¨±ÝÁõÈıº
  • Mallory-Weiss syndrome
    ¸»·Î¸®¹ÙÀ̽ºÁõÈıº
  • Marfan syndrome
    ¸¶¸£ÆÇÁõÈıº
  • myelodysplastic syndrome
    °ñ¼öÇü¼ºÀÌ»óÁõÈıº
  • nephritic syndrome
    ÄáÆÏ¿°ÁõÈıº
  • nephrotic syndrome
    ÄáÆÏÁõÈıº, ½ÅÁõÈıº
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
  • overuse syndrome
    °úµµ»ç¿ëÁõÈıº
  • paraneoplastic syndrome
    ½Å»ý¹°µþ¸²ÁõÈıº
  • Parkinson's syndrome
    ÆÄŲ½¼ÁõÈıº
  • polycystic ovarian syndrome
    ´Ù³¶³­¼ÒÁõÈıº, ¹µÁָӴϳ­¼ÒÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • alkylating agent
    ¾Ëųȭ¾à¹°, ¾ËųȭÁ¦
  • anesthetic agent
    ¸¶ÃëÁ¦
  • anorectic agent
    ½Ä¿å°¨ÅðÁ¦
  • anti-inflammatory agent
    Ç׿°ÁõÁ¦, ¼Ò¿°Á¦, ¿°Áõ¾à
  • antiallergic agent
    ¾Ë·¹¸£±â¾à
  • antiarrhythmic agent
    Ç׺ÎÁ¤¸ÆÁ¦
  • antiasthmatic agent
    (¢¡antasthmatic) Ç×õ½ÄÁ¦
  • antifoaming agent
    Ç×±âÆ÷Á¦, ±âÆ÷Á¦°ÅÁ¦
  • antifungal agent
    Ç×Áø±ÕÁ¦
  • antimetabolic agent
    Ç×´ë»ç¹°Áú
  • antitumor agent
    Ç×¾ÏÁ¦
  • antiviral agent
    Ç×¹ÙÀÌ·¯½ºÁ¦, Ç×¹ÙÀÌ·¯½º¹°Áú
  • autonomic blocking agent
    ÀÚÀ²½Å°æÂ÷´ÜÁ¦
  • bacteriostatic agent
    Á¤±ÕÁ¦
  • biologic agent
    »ý¹°ÇÐÀûÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antimycotic agent
    Ç×Áø±Õ¾à(ù÷òØÐ¶å·).
  • antineoplastic agent
    Ç×Á¾¾çÁ¦.
  • antineoplastic agent
    Ç×Á¾¾ç¼º¹°Áú
  • antiparasympathetic agent
    Ç׺α³°¨½Å°æ(¼º)¾à(ù÷ÜùÎßÊïãêÌè(àõ)å·£©.
  • antiplatelet agent
    Ç×Ç÷¼ÒÆÇÁ¦(ù÷úìá³÷ùð¥).
  • antituberculous agent
    Ç×°áÇÙ¾à(ù÷Ì¿ú·å·).
  • antitumor agent
    Ç×Á¾¾çÁ¦, Ç×Á¾¾ç¹°Áú
  • antitumor agent
    Ç׾Ͼà(ù÷äßå·), Ç×Á¾¾ç(¼º)¾à.
  • antitumor agent
    Ç׾Ͼà(ù÷ å·), Á¦¾Ï¾à(ð¤ å·), Ç×Á¾¾ç(¼º)¾à(ù÷ðþåËàõå·), Ç×Á¾¾ç(¼º)ÀÎÀÚ.
  • antiviral agent
    Ç×¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½º¹°Áú, Ç×¹ÙÀÌ·¯½ºÀÎÀÚ, Ç×¹ÙÀÌ·¯½ºÁ¦Á¦.
  • antiviral agent
    Ç×¹ÙÀÌ·¯½º¹°Áú
  • antiviral agent =a. drug
    Ç×¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½º¹°Áú, Ç×¹ÙÀÌ·¯½ºÀÎÀÚ.
  • appetite stimulating agent
    ½Ä¿åÃËÁø¾à(¡­õµòäå·).
  • appetite stimulating agent
    ½Ä¿åÀÚ±ØÁ¦
  • appetite suppressing agent
    ½Ä¿å¾ïÁ¦¾à(¡­åäð¤å·).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • toxic eczema
    Áßµ¶¼º½ÀÁø(¡­ã¥òÖ)
  • toxic edema
    Áßµ¶¼ººÎÁ¾
  • toxic effect
    Áßµ¶È¿°ú(¡­üùÍý).
  • toxic effect
    µ¶¼ºÈ¿°ú
  • toxic effect curve
    µ¶¼º°î¼±(Ô¸àõÍØàÊ).
  • toxic epidermal necrolysis
    µ¶¼ºÇ¥ÇDZ«»ç
  • toxic epidermal necrolysis
    µ¶¼ºÇ¥ÇÇÀ¶ÇØ(Ô¸ àõøúù«ë×ú°).
  • toxic epidermal necrolysis
    µ¶¼º Ç¥ÇÇÀ¶ÇØ
  • toxic equivalent
    µ¶¼ºµî°¡¹°(Ô¸àõÔõʤڪ).
  • toxic erythema
    Áßµ¶¼ºÈ«¹Ý
  • toxic erythema
    Áßµ¶¼ºÈ«¹Ý
  • toxic exanthema
    µ¶¼º¹ßÁø
  • toxic exanthema
    Áßµ¶Áø(ñéÔ¸òÖ)
  • toxic gastritis =g. toxica
    Áßµ¶¼ºÀ§¿° (¡­êÖæú)
  • toxic glycosuria
    Áßµ¶¼º´ç´¢(¡­ÓØèñ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • sulfating agent
    Ȳ»êÈ­Á¦ (üÜß«ûùð¥)
  • surface-active agent
    Ç¥¸éȰ¼ºÁ¦ (øúØüüÀàõð¥)
  • transport agent
    ¼ö¼ÛÁ¦(âÃáêð¥)
  • uncoupling agent
    ¦Ǯ±âÁ¦(ð¥)
  • wetting agent
    ½ÀÆ÷Á¦(ã¥øÖð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • medial medullary syndrome
    ³»Ãø¿¬¼öÁõÈıº
  • Meniere's syndrome
    ¸Þ´Ï¿¡¸£ÁõÈıº
  • middle lobe syndrome
    Áß¿±ÁõÈıº
  • mucocutaneous lymph node syndrome
    ÇǺÎÁ¡¸·¸²ÇÁÀýÁõÈıº
  • mucocutaneous ocular syndrome
    ÇǺÎÁ¡¸·¾ÈÁõÈıº
  • nephrotic syndrome
    ½ÅÁõÈıº, ³×ÇÁ·Î½Ã½ºÁõÈıº
  • omental adhesion syndrome
    ´ë¸Á¸·À¯ÂøÁõÈıº
  • overlap syndrome
    ÁßøÁõÈıº
  • Pancoast syndrome
    ÆÇÄÚ½ºÆ® ½Åµå·Ò
  • parietooccipital syndrome
    µÎÁ¤¿±Èĵο±ÁõÈıº
  • peutz-Jegher's syndrome
    Æ÷ÀÌÃ÷-¿¹°ÅÁõÈıº
  • PIE syndrome
    È£»ê±¸¼ºÆóħ½ÀÁõÈıº
  • Poland syndrome
    Æú¶õµåÁõÈıº
  • posterior interosseous syndrome
    Èİñ°£ÁõÈıº
  • postgastrectomy syndrome
    À§ÀýÁ¦ÈÄÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
RS radioscaphoid; random sample; rating schedule; Raynaud syndrome; recipient's serum; rectal sinus; re...
TSS Toxic Shock Syndrome
TSST-1 Toxic Shock Syndrome Toxin-1
  = Enterotoxin type F
ODTS organic dust toxic syndrome
STSS staphylococcal toxic shock syndrome
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
BCA bifunctional chelating agent
CA contrast agent
CPA cryoprotective agent
ATSDR Agency for Toxic Substances and Disease Registry
TEN Toxic epidermal necrolisis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cholinergic blocking agent
    Ç×Äݸ°¾à, Äݸ°¼º Â÷´ÜÁ¦
  • competitive agent
    °æÇÕÁ¦
  • compounding agent
    ¹èÇÕÁ¦, Á¶ÇÕÁ¦
    µ¿ÀǾî=com
  • contraceptive agent
    ÇÇÀÓÁ¦
  • cooling agent
    ³Ã°¢Á¦
  • coupling agent
    °áÇÕÁ¦, Ä¿ÇøµÁ¦
    ·¹Áø ±âÁú°ú ÇÊ·¯ÀÇ »çÀÌ¿¡ Á¸ÀçÇÏ¿© ¾çÀÚ¸¦ È­ÇÐÀûÀ¸·Î °áÇÕ½Ã۰í, Á¢Âø È¿°ú¸¦ ³ôÀÌ´Â ¹°Áú. ÀϹÝÀûÀ¸·Î ½Ç¶õÁ¦°¡ ÀÌ¿ëµÇ°í ÀÖ´Ù.
  • cross linking agent
    °¡±³Á¦
    ¼±»ó °íºÐÀÚÀÇ ºÐÀÚ°£À» È­ÇÐÀûÀ¸·Î °áÇÕÇϰí, ±×¹° ±¸Á¶¸¦ ¸¸µå´Â ÀÛ¿ëÀ» °®´Â ¹°Áú.
  • cryoprotective agent
    µ¿ÇØ º¸È£ ¾à
  • curariform agent
    Å¥¶ó·¹¾ç ¾à
  • cytostatic agent
    ¼¼Æ÷ Áõ½Ä ¾ïÁ¦ ¾à¹°
  • defoaming agent
    ¼ÒÆ÷Á¦
  • dehydrating agent
    Å»¼öÁ¦
    ü¾×ÀÇ Á¦°Å ¶Ç´Â °¨¼Ò½ÃŰ´Â ¾à¹°.
  • dentin bonding agent
    »ó¾ÆÁú Á¢ÂøÁ¦
    Ä¡°ú º¸Á¸ Ä¡·á ½Ã »ç¿ëÇÏ¸ç »ó¾ÆÁúÀ» ´Ù¸¥ º¸Ã¶¹°¿¡ Á¢Âø½Ã۱â À§ÇØ »ç¿ëµÈ´Ù.
  • developing agent
    Çö»ó ÁÖ¾à
  • douching : a jet or current of water, sometimes a dissolved medicating or cleansing agent, applied to a body part, organ or cavity for medicinal or hygienic purposes.

    dough

    ¹ÝÁ×ÇÑ °Í, ³¯ ºÐ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
antidiabetic agent A substance that helps a person with diabetes control the level of glucose (sugar) in the blood so that the body works as it should. See: insulin.
(09 Oct 1997)
antifibrinolytic agent Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive haemorrhage and in other coagulation disorders.
(12 Dec 1998)
antifoam agent A chemical that reduces the surface tension of foams that form on thesurface of broths in fermentors because of aeration or agitation. Stearyldecanol, octal decanol, vegetable oils, silicones, sulphonates, andpolypropylene glycol are typically used, though they can cause problems inrefining the broth later on.
(09 Oct 1997)
anti-inflammatory agent Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
anti-inflammatory agent, steroidal Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents.
(12 Dec 1998)
anti-inflammatory agent, topical Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application.
(12 Dec 1998)
antinematodal agent Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice.
(12 Dec 1998)
antineoplastic agent Agents inhibiting or preventing the growth of neoplasms, checking the maturation and proliferation of malignant cells.
(12 Dec 1998)
antineoplastic agent, alkylating A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumour efficacy and the presence in their chemical structures of n-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumour cells are not completely understood.
(12 Dec 1998)
antineoplastic agent, combined The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
(12 Dec 1998)
antineoplastic agent, hormonal Antineoplastic agent that are used to treat hormone-sensitive tumours. Hormone-sensitive tumours may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumour regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumours may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukaemias.
(12 Dec 1998)
antineoplastic agent, phytogenic Agents, obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
(12 Dec 1998)
antipsychotic agent A functional category of neuroleptic drugs that are helpful in the treatment of psychosis and have a capacity to ameliorate thought disorders (e.g., chlorpromazine, haloperidol).
See: neuroleptic.
Synonym: antipsychotic, major tranquilliser.
(05 Mar 2000)
antithyroid agent <pharmacology> Medications which suppress thyroid function.
Examples include methimazole and propylthiouracil.
(13 Jan 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • universal agent
    ÃѴ븮Á¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á